Vertical Sleeve Gastrectomy for Non-alcoholic Fatty Liver Disease (NAFLD)
Phase-Based Progress Estimates
Effectiveness
Safety
University of San Fransisco, San Francisco, CANon-alcoholic Fatty Liver Disease (NAFLD)Vertical Sleeve Gastrectomy - Procedure
Study Summary
This trial is testing whether a lifestyle modification or a Vertical Sleeve Gastrectomy (VSG) is more effective in reducing non-alcoholic steatohepatitis (NASH) score.
Eligible Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Month 12
Month 12
Histologic improvements in NAFLD Activity Score (NAS)
Trial Safety
Safety Progress
Trial Design
2 Treatment Groups
LSM
1 of 2
VSG + LSM
1 of 2
Active Control
Experimental Treatment
48 Total Participants · 2 Treatment Groups
Primary Treatment: Vertical Sleeve Gastrectomy · No Placebo Group · N/A
VSG + LSMExperimental Group · 2 Interventions: Vertical Sleeve Gastrectomy, Lifestyle Modification Counseling · Intervention Types: Procedure, Behavioral
LSM
Behavioral
ActiveComparator Group · 1 Intervention: Lifestyle Modification Counseling · Intervention Types: BehavioralTreatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vertical Sleeve Gastrectomy
2009
N/A
~140
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 12
Who is running the clinical trial?
University of MinnesotaLead Sponsor
1,271 Previous Clinical Trials
1,487,944 Total Patients Enrolled
Sayeed Ikramuddin, M.D., M.H.A.Principal InvestigatorUniversity of Minnesota
Eligibility Criteria
Age 40 - 67 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: